Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study.

ABSTRACT:

Background

Nivolumab therapy is a standard-of-care treatment for heavily pretreated patients with advanced gastric cancer (AGC). Previous studies have reported improvement in the objective response rate to chemotherapy after nivolumab therapy for other types of cancer. This study evaluated the efficacy and safety of chemotherapy after nivolumab therapy in AGC.

Patients and methods

We conducted a prospective, multicenter, observational study in pretreated patients with nivolumab-refractory or -intolerant AGC. Patients received irinotecan, oxaliplatin-containing regimens, or trifluridine/tipiracil. The primary endpoint was overall survival.

Results

A total of 199 patients were included (median age: 69 years; male: 70%; female: 30%). Median overall survival and progressi

SUBMITTER: Narita Y 

PROVIDER: S-EPMC10774960 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature